Women and Coronary Artery Disease

  • Nishath A. Quader
  • Susan Wilansky
Part of the Cardiovascular Medicine book series (CVM)


Coronary artery disease was long considered to be a disease primarily affecting men. However, recent statistics indicate that it is also the most frequent cause of death in women. Awareness campaigns have tried to address the disparities in knowledge regarding women and coronary artery disease. This chapter highlights some of the differences and similarities in treatment strategies for women compared with those for men. It also reviews some of the causes of chest pain in women and various diagnostic modalities.


Chest pain Coronary artery disease Nonobstructive causes of chest pain Risk factors Women 



American College of Cardiology


American Heart Association


Coronary artery calcification


Coronary artery disease


Cholesterol and Recurrent Events


Coronary Artery Surgery Study


Carotid intima media thickening


Can Rapid Risk Stratification of Unstable Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines


Fragmin and Fast Revascularization During Instability in Coronary Artery Disease


Glycoprotein IIB/IIIa


Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndrome


High-density lipoprotein


High-density lipoprotein cholesterol


Heart and Estrogen/progestin Replacement Study follow-up


Hazard ratio


Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure


Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin


Low-density lipoprotein


Low-density lipoprotein cholesterol


Measuring Effects on Intima-Media Thickness: An Evaluation of Rosuvastatin


National Cholesterol Education Program


Non–ST-elevation myocardial infarction


Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22


Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy


Relative risk


ST-elevation myocardial infarction


Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy–Thrombolysis in Myocardial Infarction 18


Thrombolysis in Myocardial Infarction


Women’s Health Initiative


Women’s Ischemia Syndrome Evaluation


  1. 1.
    National Institutes of Health; National Heart, Lung, and Blood Institute. Fact book: fiscal year 2010 [Internet]. Washington (DC): US Department of Health and Human Services; [cited 26 Jun 2012]. Available from:
  2. 2.
    Lewis SJ. Cardiovascular disease in postmenopausal women: myths and reality. Am J Cardiol. 2002;89(12A):5E–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of American women’s awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes. 2010;3(2):120–7.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Doroodchi H, Abdolrasulnia M, Foster JA, Foster E, Turakhia MP, Skelding KA, et al. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract. 2008;9:42.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Barnhart J, Lewis V, Houghton JL, Charney P. Physician knowledge levels and barriers to coronary risk prevention in women: survey results from the Women and Heart Disease Physician Education Initiative. Womens Health Issues. 2007;17(2):93–100.PubMedCrossRefGoogle Scholar
  6. 6.
    Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women. Circulation. 1993;88(4 Pt 1):1999–2009.PubMedCrossRefGoogle Scholar
  7. 7.
    Lurie N, Fremont A, Jain AK, Taylor SL, McLaughlin R, Peterson E, et al. Racial and ethnic disparities in care: the perspectives of cardiologists. Circulation. 2005;111(10):1264–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis. 2007;17(1):143–52.PubMedGoogle Scholar
  9. 9.
    Palaniappan LP, Araneta MR, Assimes TL, Barrett-Connor EL, Carnethon MR, Criqui MH, et al. Call to action: cardiovascular disease in Asian Americans: a science advisory from the American Heart Association. Circulation. 2010;122(12):1242–52. Erratum in: Circulation. 2010;122(19):e516. Council on Cardiovascular Nursing [added].Google Scholar
  10. 10.
    Nasir K, Shaw LJ, Liu ST, Weinstein SR, Mosler TR, Flores PR, et al. Ethnic differences in the prognostic value of coronary artery calcification for all-cause mortality. J Am Coll Cardiol. 2007;50(10):953–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation. 2008;117(14):1787–801.PubMedCrossRefGoogle Scholar
  12. 12.
    Watkins LO. Epidemiology and burden of cardiovascular disease. Clin Cardiol. 2004;27(6 Suppl 3):III2–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Parikh SV, Enriquez JR, Selzer F, Slater JN, Laskey WK, Wilensky RL, et al. Association of a unique cardiovascular risk profile with outcomes in Hispanic patients referred for percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol. 2009;104(6):775–9. Epub 2009 Jul 25.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    van Ryn M, Burgess D, Malat J, Griffin J. Physicians’ perceptions of patients’ social and behavioral characteristics and race disparities in treatment recommendations for men with coronary artery disease. Am J Public Health. 2006;96(2):351–7.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.PubMedCrossRefGoogle Scholar
  16. 16.
    Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9. Erratum in: JAMA. 2007;297(13):1433.Google Scholar
  17. 17.
    Blair ML. Sex-based differences in physiology: what should we teach in the medical curriculum? Adv Physiol Educ. 2007;31(1):23–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243–62. Errata in: Circulation. 2011;124(16):e427. Circulation. 2011;123(22):e624.Google Scholar
  19. 19.
    Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CN, Lauer MS, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med. 2005;353(5):468–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72. Epub 2003 May 14. Erratum in: JAMA. 2003;290(2):197.Google Scholar
  21. 21.
    Zanchetti A, Facchetti R, Cesana GC, Modena MG, Pirrelli A, Sega R. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. J Hypertens. 2005;23(12):2269–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Ramirez-Exposito MJ, Martinez-Martos JM. Hypertension, RAS, and gender: what is the role of aminopeptidases? Heart Fail Rev. 2008;13(3):355–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Hernandez Schulman I, Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol. 2006;26(2):170–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Butkevich A, Abraham C, Phillips RA. Hormone replacement therapy and 24-h blood pressure profile of postmenopausal women. Am J Hypertens. 2000;13(9):1039–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al.; The INDANA Investigators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. Ann Intern Med. 1997;126(10):761–7.Google Scholar
  26. 26.
    Frazier CG, Shah SH, Armstrong PW, Bhapkar MV, McGuire DK, Sadowski Z, et al. Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. Am Heart J. 2005;150(6):1260–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension. 2000;36(5):780–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med. 2002;5(2):27–37.PubMedGoogle Scholar
  29. 29.
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRefGoogle Scholar
  30. 30.
    Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas. 1990;12(4):321–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Bittner V. Lipoprotein abnormalities related to women’s health. Am J Cardiol. 2002;90(8A):77i–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115(11):1481–501. Erratum in: Circulation. 2007;115(15):e407.Google Scholar
  33. 33.
    Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T, et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation. 2008;117(4):494–502.PubMedCrossRefGoogle Scholar
  34. 34.
    Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation. 2004;110(18):2824–30.PubMedCrossRefGoogle Scholar
  36. 36.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.Google Scholar
  37. 37.
    Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332(26):1758–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993;22(7):1788–94.PubMedCrossRefGoogle Scholar
  39. 39.
    Kanaya AM, Herrington D, Vittinghoff E, Lin F, Bittner V, Cauley JA, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med. 2005;142(10):813–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Hu G, Jousilahti P, Qiao Q, Peltonen M, Katoh S, Tuomilehto J. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol. 2005;45(9):1413–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness Jr E. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med. 1984;311(15):953–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women: The Framingham Study. JAMA. 1988;260(23):3456–60. Erratum in: JAMA 1989;261(13):1884Google Scholar
  45. 45.
    Wong ND, Pio JR, Franklin SS, L’Italien GJ, Kamath TV, Williams GR. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol. 2003;91(12):1421–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol. 2005;162(11):1089–97.PubMedCrossRefGoogle Scholar
  47. 47.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.PubMedCrossRefGoogle Scholar
  48. 48.
    Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317(21):1303–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Douglas P, editor. Cardiovascular health and disease in women. 1st ed. Philadelphia: Saunders; 1993.Google Scholar
  50. 50.
    Gramenzi A, Gentile A, Fasoli M, D’Avanzo B, Negri E, Parazzini F, et al. Smoking and myocardial infarction in women: a case-control study from northern Italy. J Epidemiol Community Health. 1989;43(3):214–7.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Mieres JH, Shaw LJ, Arai A, Budoff MJ, Flamm SD, Hundley WG, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation. 2005;111(5):682–96.PubMedCrossRefGoogle Scholar
  52. 52.
    Mark DB, Hlatky MA, Harrell Jr FE, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 1987;106(6):793–800.PubMedCrossRefGoogle Scholar
  53. 53.
    Mark DB, Shaw L, Harrell Jr FE, Hlatky MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991;325(12):849–53.PubMedCrossRefGoogle Scholar
  54. 54.
    Alexander KP, Shaw LJ, Shaw LK, Delong ER, Mark DB, Peterson ED. Value of exercise treadmill testing in women. J Am Coll Cardiol. 1998;32(6):1657–64. Erratum in: J Am Coll Cardiol. 1999;33(1):28.Google Scholar
  55. 55.
    Weiner DA, Ryan TJ, McCabe CH, Kennedy JW, Schloss M, Tristani F, et al. Exercise stress testing: correlations among history of angina, ST-segment response and prevalence of coronary-artery disease in the Coronary Artery Surgery Study (CASS). N Engl J Med. 1979;301(5):230–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Sullivan AK, Holdright DR, Wright CA, Sparrow JL, Cunningham D, Fox KM. Chest pain in women: clinical, investigative, and prognostic features. BMJ. 1994;308(6933):883–6.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Raggi P, Shaw LJ, Berman DS, Callister TQ. Gender-based differences in the prognostic value of coronary calcification. J Womens Health (Larchmt). 2004;13(3):273–83.CrossRefGoogle Scholar
  58. 58.
    Lester SJ, Eleid MF, Khandheria BK, Hurst RT. Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis. Mayo Clin Proc. 2009;84(3):229–33.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.
    Crouse 3rd JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’ Leary DH, et al.; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344–53. Epub 2007 Mar 25.Google Scholar
  60. 60.
    Kyker KA, Limacher MC. Gender differences in the presentation and symptoms of coronary artery disease. Curr Womens Health Rep. 2002;2(2):115–9.PubMedGoogle Scholar
  61. 61.
    McGuire DK, Newby LK, Biswas MS, Hochman JS. The elderly, women, and patients with diabetes mellitus. In: Theroux P, editor. Acute coronary syndromes: a companion to Braunwald’s heart disease. 1st ed. Philadelphia: Saunders; 2003. p. 553–73.Google Scholar
  62. 62.
    Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307(8):813–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(3 Suppl):S4–20.PubMedCrossRefGoogle Scholar
  64. 64.
    Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction: National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999;341(4):217–25.PubMedCrossRefGoogle Scholar
  65. 65.
    Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J. 1998;136(2):205–12.PubMedCrossRefGoogle Scholar
  66. 66.
    Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, et al.; The GUSTO-IIb Investigators. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation. 1998;98(18):1860–8.Google Scholar
  67. 67.
    Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002;288(24):3124–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation. 2005;111(7):940–53.PubMedCrossRefGoogle Scholar
  69. 69.
    Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344(25):1879–87.PubMedCrossRefGoogle Scholar
  70. 70.
    Lagerqvist B, Safstrom K, Stahle E, Wallentin L, Swahn E, FRISC II Study Group Investigators. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? J Am Coll Cardiol. 2001;38(1):41–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction): developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):652–726.CrossRefGoogle Scholar
  72. 72.
    Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation. 2008;117(2):296–329. Erratum in: J Am Coll Cardiol. 1999;33(1):289.Google Scholar
  73. 73.
    Hasdai D, Califf RM, Thompson TD, Hochman JS, Ohman EM, Pfisterer M, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 2000;35(1):136–43.PubMedCrossRefGoogle Scholar
  74. 74.
    Gottlieb S, Harpaz D, Shotan A, Boyko V, Leor J, Cohen M, et al. Sex differences in management and outcome after acute myocardial infarction in the 1990s: A prospective observational community-based study. Israeli Thrombolytic Survey Group. Circulation. 2000;102(20):2484–90.PubMedCrossRefGoogle Scholar
  75. 75.
    Hochman JS, Tamis-Holland JE. Acute coronary syndromes: does sex matter? JAMA. 2002;288(24):3161–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Antoniucci D, Valenti R, Moschi G, Migliorini A, Trapani M, Santoro GM, et al. Sex-based differences in clinical and angiographic outcomes after primary angioplasty or stenting for acute myocardial infarction. Am J Cardiol. 2001;87(3):289–93.PubMedCrossRefGoogle Scholar
  77. 77.
    Vakili BA, Kaplan RC, Brown DL. Sex-based differences in early mortality of patients undergoing primary angioplasty for first acute myocardial infarction. Circulation. 2001;104(25):3034–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients: Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6921):81–106. Erratum in: BMJ. 1994;308(6943):1540.Google Scholar
  79. 79.
    Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304.PubMedCrossRefGoogle Scholar
  80. 80.
    The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339(7):436–43.CrossRefGoogle Scholar
  81. 81.
    Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, et al.; CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294(24):3108–16. Erratum in: JAMA. 2006;295(6):628.Google Scholar
  82. 82.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. Erratum in: N Engl J Med. 2006;354(7):778.Google Scholar
  83. 83.
    Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93(10):1796–802. Erratum in: Circulation 1996;94(4):849.Google Scholar
  84. 84.
    Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al.; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335(14):1001–9.Google Scholar
  85. 85.
    Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–82. Erratum in: J Am Coll Cardiol. 2012;59(16):1491.Google Scholar
  86. 86.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.PubMedCrossRefGoogle Scholar
  87. 87.
    Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49–57. Erratum in: JAMA. 2002;288(9):1064.Google Scholar
  88. 88.
    Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2006;113(1):5–14.PubMedCrossRefGoogle Scholar
  89. 89.
    Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al.; the Atherosclerosis Risk in Communities Study Investigators. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328(15):1069–75.Google Scholar
  90. 90.
    Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100(7):717–22.PubMedCrossRefGoogle Scholar
  91. 91.
    Grodstein F, Manson JE, Stampfer MJ, Willett WC. The discrepancy between observational studies and randomized trials of menopausal hormone therapy. Ann Intern Med. 2004;140(9):764–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265(14):1861–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115(6):455–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW, Scott KN, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(24):2993–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Reis SE, Holubkov R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J. 2001;141(5):735–41.PubMedCrossRefGoogle Scholar
  96. 96.
    Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN, Collins P, et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med. 2002;346(25):1948–53.PubMedCrossRefGoogle Scholar
  97. 97.
    Bugiardini R, Bairey Merz CN. Angina with “normal” coronary arteries: a changing philosophy. JAMA. 2005;293(4):477–84.PubMedCrossRefGoogle Scholar
  98. 98.
    Rosen SD, Paulesu E, Wise RJ, Camici PG. Central neural contribution to the perception of chest pain in cardiac syndrome X. Heart. 2002;87(6):513–9.PubMedCentralPubMedCrossRefGoogle Scholar
  99. 99.
    Johnson BD, Shaw LJ, Pepine CJ, Reis SE, Kelsey SF, Sopko G, et al. Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women’s Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J. 2006;27(12):1408–15.PubMedCrossRefGoogle Scholar
  100. 100.
    Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N. Angina pectoris, I: a variant form of angina pectoris: preliminary report. Am J Med. 1959;27:375–88.PubMedCrossRefGoogle Scholar
  101. 101.
    Mayer S, Hillis LD. Prinzmetal’s variant angina. Clin Cardiol. 1998;21(4):243–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Okumura K, Osanai T, Kosugi T, Hanada H, Ishizaka H, Fukushi T, et al. Enhanced phospholipase C activity in the cultured skin fibroblast obtained from patients with coronary spastic angina: possible role for enhanced vasoconstrictor response. J Am Coll Cardiol. 2000;36(6):1847–52.PubMedCrossRefGoogle Scholar
  103. 103.
    Okumura K, Yasue H, Matsuyama K, Ogawa H, Kugiyama K, Ishizaka H, et al. Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin. J Am Coll Cardiol. 1996;27(1):45–52.PubMedCrossRefGoogle Scholar
  104. 104.
    Onaka H, Hirota Y, Shimada S, Kita Y, Sakai Y, Kawakami Y, et al. Clinical observation of spontaneous anginal attacks and multivessel spasm in variant angina pectoris with normal coronary arteries: evaluation by 24-hour 12-lead electrocardiography with computer analysis. J Am Coll Cardiol. 1996;27(1):38–44.PubMedCrossRefGoogle Scholar
  105. 105.
    Hung MJ, Cheng CW, Yang NI, Hung MY, Cherng WJ. Coronary vasospasm-induced acute coronary syndrome complicated by life-threatening cardiac arrhythmias in patients without hemodynamically significant coronary artery disease. Int J Cardiol. 2007;117(1):37–44.PubMedCrossRefGoogle Scholar
  106. 106.
    Yuksel UC, Celik T, Iyisoy A, Kursaklioglu H, Amasyali B, Kose S. Polymorphic ventricular tachycardia induced by coronary vasospasm: a malignant case of variant angina. Int J Cardiol. 2007;121(2):210–2.PubMedCrossRefGoogle Scholar
  107. 107.
    Pepine CJ, el-Tamimi H, Lambert CR. Prinzmetal’s angina (variant angina). Heart Dis Stroke. 1992;1(5):281–6.PubMedGoogle Scholar
  108. 108.
    Raxwal V, Gupta K. Images in cardiovascular medicine: coronary artery spasm. Circulation. 2006;113(14):e689–90.PubMedCrossRefGoogle Scholar
  109. 109.
    Chen HS, Pinto DS. Images in clinical medicine: Prinzmetal’s angina. N Engl J Med. 2003;349(1):e1.PubMedCrossRefGoogle Scholar
  110. 110.
    Bory M, Pierron F, Panagides D, Bonnet JL, Yvorra S, Desfossez L. Coronary artery spasm in patients with normal or near normal coronary arteries: long-term follow-up of 277 patients. Eur Heart J. 1996;17(7):1015–21.PubMedCrossRefGoogle Scholar
  111. 111.
    Shimokawa H, Nagasawa K, Irie T, Egashira S, Egashira K, Sagara T, et al. Clinical characteristics and long-term prognosis of patients with variant angina: a comparative study between western and Japanese populations. Int J Cardiol. 1988;18(3):331–49.PubMedCrossRefGoogle Scholar
  112. 112.
    Hurst RT, Prasad A, Askew 3rd JW, Sengupta PP, Tajik AJ. Takotsubo cardiomyopathy: a unique cardiomyopathy with variable ventricular morphology. JACC Cardiovasc Imaging. 2010;3(6):641–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol. 2004;43(10):1791–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Division of Cardiovascular DiseasesWashington University School of MedicineSt. LouisUSA
  2. 2.Division of Cardiovascular DiseasesMayo ClinicScottsdaleUSA
  3. 3.Medicine DepartmentCollege of Medicine, Mayo ClinicRochesterUSA

Personalised recommendations